Join us at the cutting edge of oncology innovation. In this role, you will immerse yourself in the exciting and innovative field of liquid-biopsy based biomarker investigation in oncology with direct application to our internal project’s portfolio.
Liquid biopsies represent a major advance in the molecular diagnostic space and are increasingly used in clinical trials. By replacing invasive tissue biopsies with minimally invasive blood sampling, They facilitate patient recruitment, enable earlier assessment of treatment response, and improve identification of appropriate patient populations. In addition, they provide valuable insight into disease biology and support the development of predictive and prognostic biomarkers. Debiopharm is now expanding the implementation of these technologies across our portfolio.
As an intern in the Personalised Medicine team, part of the Translation Medicine Team, you will participate in fore-front clinical investigations, contribute directly to patient-centric clinical trials design and help shape the future of targeted oncology therapies.
Requirements
Working under the guidance and mentorship of an Associate Principal Scientist, your core responsibilities will be but not limited to:
Your profile
Benefits
If your application is selected, you’ll be invited to interviews with Talent Acquisition and the Hiring Manager via Teams, followed by a panel interview and reference checks. Communication is handled via Workable—check your spam folder for emails from *@outbound.workable.com.
Please contact our HR Department prior to submitting any profiles. We cannot accept unsolicited applications from agencies or recruiters.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe.
Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections.
Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®
If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!